Key Stats for Intuitive Surgical Stock
- Current Price: $369.15
- Target Price (Mid): ~$585
- Street Target: ~$476
- Potential Total Return: ~59%
- Annualized IRR: ~11% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Intuitive Surgical (ISRG) spent 2026 being punished for a problem most companies would envy: it is still growing revenue near 20%, and the market decided that was not enough. Shares closed at $369.15 on September 11, roughly 39% below the January 2025 peak near $610, after U.S. procedure growth slowed and new soft-tissue rivals reached the market. The fear is that the U.S. deceleration is structural.
Then, on September 8, the company put fresh evidence on the table. Intuitive co-published a peer-reviewed meta-analysis, led by Thomas H. Shin, a bariatric surgeon at Mass General Brigham, with researchers from the University of Virginia. It covers more than 14 million procedures across 13 benign conditions, and it lands on the exact part of the business that bears fear most.
The Evidence Is Aimed at the Weak Spot
The bear case is about benign general surgery, the gallbladder and hernia procedures management is counting on to re-accelerate U.S. growth.
Published in Annals of Surgery Open, it synthesized 14 years of data from 32 countries. Against laparoscopic surgery, da Vinci showed no statistically significant difference in complications or 30-day mortality, with operative times about 24 minutes longer. Against open surgery, the gap was clearer: lower odds of complications, readmission, reoperation, and mortality, plus 37% lower odds of needing pain medication within 30 days. Intuitive calls it the largest comparison of its kind. It is not a clean sweep, and the company says so, but it hands surgeons evidence in the category with the most adoption headroom left.
At the Wells Fargo Healthcare Conference on September 9, CFO Jamie Samath was asked whether U.S. procedure growth could fall below 10% in the second half. He declined to guide regionally but reaffirmed the global range of 13.5% to 15.5%, saying growth is “likely to be towards the midpoint.” His framework is procedure by procedure: cholecystectomy, the largest U.S. category, sits only in the second quartile of adoption, while cardiac and nipple-sparing mastectomy are just entering the funnel. Evidence that robotic surgery holds up in benign cases is the fuel that the curve needs.
See historical and forward estimates for Intuitive Surgical stock (It’s free!) >>>
The Slowdown Is Real, But the Numbers Aren’t Breaking
Samath cited a modest hit from lower ACA subsidies, already flagged, plus bariatric surgery, once a driver and now a drag. Asked whether it had troughed, he was candid: “the decline hasn’t yet approached 0.” Dan Connally, head of investor relations, noted U.S. bariatrics has shrunk from a little over 5% of global da Vinci procedures to a little over 2%, so the incremental damage is fading even as the decline continues.
Q2 revenue of $2,892.30 million beat the Street by 2.38%, and adjusted EPS of $2.80 beat by nearly 12%. EBIT margin hit 42.11% in the quarter. Samath’s closing pitch was a dare to read the P&L: first-half revenue growth of 21%, EPS growth above 30%, and a free cash flow margin of 31%, “about as high as we’ve done in our history.” The market priced deceleration all year while the numbers kept climbing.
Medtronic’s Hugo was the first large-cap soft-tissue robot to clear the FDA since Intuitive, winning a urology indication in December 2025, and Medtronic has since filed Hugo for general surgery and gynecology, the exact categories that drive most da Vinci volume. Johnson & Johnson’s Ottava followed with its own clearance in July 2026. Two credible challengers arriving inside a year is a real reason the multiple compressed from roughly 61 times forward earnings at the end of 2025 to about 33 times now. Samath’s answer is that the basis of competition is the full ecosystem, not the robot alone, and he expects rivals to need “a couple of years” to scale against it. A business with a 66.7% gross margin and mid-teens forward growth rarely trades this cheap, and it does now because those competitive worries landed alongside the U.S. slowdown in the same stretch.
See how Intuitive Surgical performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $369.15
- Target Price (Mid): ~$585
- Potential Total Return: ~59%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for Intuitive Surgical stock (It’s free!) >>>
The model uses the mid case, which fits an article asking whether today’s price is a floor. It targets around $585 by the end of 2030, a total return of roughly 59%, or about 11% a year over 4.3 years.
- Revenue driver 1: Benign general surgery, the early-adoption procedures now backed by fresh outcomes evidence.
- Revenue driver 2: International expansion, where lower penetration and the segmented X and XiR portfolio open cost-constrained markets.
- Margin driver: Operating leverage, as the installed base scales fixed costs faster than spending grows, lifting first-half operating margin to 41%.
- Primary risk: Rival scale-up. If Medtronic’s Hugo wins its general-surgery and gynecology labels and J&J’s Ottava ramps faster than expected, the selling cycle elongates and both placements and the multiple suffer.
The upside: benign adoption re-accelerates on the new evidence and the multiple stabilizes, delivering the mid-case return. The downside: competition and U.S. deceleration prove structural, and even low-double-digit revenue growth cannot hold a premium the market has stopped paying. For context, the Street mean target sits near $476, between today’s price and the model’s mid case.
Conclusion
The next real test is the Q3 2026 print, expected in October, though not yet formally dated. Two things resolve there. First, whether U.S. procedure growth held above 10% in the second half, the question Samath sidestepped at Wells Fargo. Second, the extended-use instrument program, which management will quantify on the Q3 call, and which is built to stimulate benign procedure volume through lower per-use costs. Good looks like global procedure growth at or above the 14.5% midpoint with no further U.S. slippage. Bad looks like a sub-10% U.S. number that turns the debate structural. Until then, the September evidence is the bulls’ best card, and it is pointed at the right target.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Intuitive Surgical?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Intuitive Surgical, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Intuitive Surgical on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
